NCT03157128: A reported trial by Eli Lilly and Company
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03157128 |
|---|---|
| Title | A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001) |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | May 2, 2017 |
| Completion date | Feb. 14, 2025 |
| Required reporting date | Feb. 14, 2026, midnight |
| Actual reporting date | Feb. 13, 2026 |
| Date last checked at ClinicalTrials.gov | May 15, 2026 |
| Days late | None |